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Abstract
Background: Neoadjuvant chemotherapy for potentially resectable metastatic colorectal cancer (MCC)
is becoming a more common treatment algorithm. The aim of the present study was to evaluate the
efficacy of precision hepatic arterial Irinotecan therapy in unresectable MCC.
Methods: An open-label, multi-centre, multi-national single arm study of MCC patients, who received
hepatic arterial irinotecan. Primary endpoints were safety, tolerance and metastatic tumour resection.
Results: Fifty-five patients with metastatic colorectal to the liver underwent a total of 90 hepatic arterial
irinotecan treatments. The extent of liver involvement was <25% in 75% of the patients (n = 41), between
26 and 50% in 15% of the patients (n = 11) and >50% in 10% of the patients (n = 24). The median number
of hepatic lesions was four (range 1–20), with a median total size of all target lesions of 9 cm (range
5.5–28 cm) with 50% of patients having bilobar tumour distribution. The median number of irinotecan
treatments was two (range 1–5). The median treatment dose was 100 mg (range 100–200) with a median
total hepatic treatment of 200 mg (range 200–650). The majority of treatments (86%) were performed as
lobar infusion treatments, and 30% of patients were treated with concurrent simultaneous chemotherapy.
Eleven (20%) patients demonstrated significant response and downstage of their disease or demon-
strated stable disease without extra-hepatic disease progression allowing resection, ablation or resection
and ablation. There were no post-operative deaths. Post-operative complications morbidity occurred in
18% of patients, with none of them hepatic related. Non-tumorous liver resected demonstrated no
evidence of steatohepatitis from the irinotecan arterial infusion.
Conclusions: Hepatic arterial infusion irinotecan drug-eluting beads is safe and effective in pre-surgical
therapy and helpful in evaluating the biology of metastatic colorectal cancer to the liver prior to planned
hepatic resection.
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Introduction
Hepatic metastasis of colorectal cancer (MCC) is quite common
occurring at some time in 23% of all of the 190 000 colorectal
patients diagnosed each year.1 While systemic chemotherapy can
slow growth and even cause regression of hepatic metastases,
long-term survival without local therapy is unlikely. Surgical
resection of hepatic metastases continues to remain the optimal
first-line treatment for hepatic colorectal metastases. Other local
therapies that have been used are transarterial chemotherapy,
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ethanol injection, cryotherapy, radiofrequency ablation and
microwave ablation. The role of hepatic transarterial therapy of
hepatic colorectal metastases continues to evolve as the technol-
ogy evolves and experience with this technique matures.2 There
have been recent reports of precision transarterial therapy in
metastatic colorectal cancer with acceptable results.3,4
Patients presenting with initially unresectable metastatic col-
orectal metastasis either by a number of lesions or extrahepatic
metastatic disease have the benefit of systemic 5 fluorouracil (FU)-
based chemotherapy with a combination of oxaliplatin and/or
irinotecan which offers a high rate of response (35–50%) and a
longer median survival (15–20 months) vs. historical observation
or 5 fluorouracil monotherapy alone.5–7 However, patients who are
refractory to 5FU-based systemic chemotherapy in combination
with oxaliplatin rarely show a durable clinically relevant response
rate for second or third line chemotherapy.8 In a majority of
patients, the most common site of refractory progression is within
the liver. Thus, a minimally invasive hepatic-directed therapy that
could potentially accentuate response rates as amonotherapy or in
combination with systemic therapy is greatly needed.
Despite the advances in development of new cytotoxics and
targeted biologics for the treatment of hepatic metastases from
colorectal cancer, there is still interest in liver directed locoregional
therapy to improve treatment response and potentially improve
survival. Transarterial chemoembolization (TACE) is a locore-
gional therapy that is most widely used for the treatment of unre-
sectable hepatocellar carcinoma (HCC).9,10 It involves the periodic
injection of a chemotherapeutic agent, mixed with an embolic
material, into selected branches of the hepatic arteries feeding a
liver tumour. A normal liver receives approximately 90% of its
blood supply from the portal vein and 20% from branches of the
hepatic artery.11 In contrast, metastasis to the liver are hypervas-
cular and receive their blood supply almost exclusively from the
hepatic artery. The process of TACE involves the infusion of drugs
such as irinotecan, doxorubicin, mitomycin C and cisplatin, with
a viscous material (e.g. lipiodol) followed by embolization of the
blood vessel with gelfoam, polyvinyl alcohol (PVA) particles or
spherical embolic agents that will occlude arterial blood supply to
the tumour. Therefore, two antitumoural mechanisms are acting
together: the ischaemic insult related to the mechanical occlusion
of the feeding arteries and the cytotoxic insult as a result of the
targeted delivery of cytotoxic agents mixed with lipiodol, an oil
that is specifically retained by neoplastic cells. A modification of
this technique is the use of drug-eluting beads that combine the
process of drug delivery and embolization in a single agent. The
beads also allow for drug elution over days to weeks instead of a
single infusion.12,13 The expected advantage of TACE is that higher
concentrations of the drug can be delivered to the tumour with
decreased systemic exposure compared with systemic chemo-
therapy. Thus, the aim of this study was to evaluate the efficacy of
precision hepatic arterial irinotecan therapy in unresectable MCC
and evaluate the effectiveness of response to allow for surgical
resection.
Materials and methods
An Institutional Review Board approved prospective multi-
institutional open, non-controlled, repeat treatment registry was
evaluated from January 2007 to October 2008 in which 50 patients
presenting with liver dominant metastatic colon cancer (MCC) to
the liver were treated with irinotecan drug-eluting beads.
Included were patients 8 years of age, of any race or gender, and
had histological or radiological proof of MCC to the liver. Patients
must also have had an ECOG performance status score of less than
or equal to 2 with a life expectancy of greater than 3 months.
Treatment of pre-menopausal women was permitted with an
acceptable contraceptive. Exclusion to therapy was contraindica-
tion to angiographic and selective visceral catheterization, signifi-
cant extrahepatic disease representing an eminent life-threatening
outcome, greater than 75% of hepatic parenchymal involvement,
severe liver dysfunction, pregnancy and severe cardiac
co-morbidities. Only patients with liver dominant (defined as
greater than 50% of the overall total disease burden) were consid-
ered for treatment.
Standard pre-therapy evaluation of patients with MCC
included at least a three-phase computed tomography (CT) of the
abdomen and pelvis and chest roentgenogram at least 1 month or
less prior to treatment, with the use of positron emission tomog-
raphy (PET) scanning depending on the institution and the avail-
ability of the technology. Prior systemic chemotherapy of any type
and duration was allowed and was recorded.
Patients were followed for any treatment-related adverse expe-
riences for 30 days after each treatment, and monitored for sur-
vival for 2 years. All adverse events from the chemotherapy were
recorded per standards and terminology set forth by the Cancer
Therapy Evaluation Program Common Terminology Criteria for
Adverse Events, Version 3.0. Follow-up assessments included a
tri-phase CT scan of the liver within at least 1 to 2 months from
the treatment completion with the evaluation of the enhancement
pattern of the target lesion and tumour response rates measured
according to RECIST, EASL,14 and modified RECIST15 criteria.
Hepatic angiogram
A diagnostic angiography was performed by the interventional
radiologist and consisted of selective celiac and superior mesen-
teric arteriograms to evaluate the hepatic arterial anatomy. Defin-
ing the amount of liver disease was integral to defining both the
number of treatments and the type of catheter position and
therapy that would be performed. For finite numbers of lesions
defined as less than four lesions (or <25% liver tumour burden),
the treatment plan consisted of a minimum of two dosing sched-
ules of at least 50 mg to 100 mg of irinotecan loaded in one to two
DC/LC bead vials of either 100–300 microns, 300–500 microns or
500–700 microns. Treatments were scheduled at 3- to 4-week
intervals and extended based on the toxicity. Most patients fol-
lowed a plan of either two to three treatments based on the extent
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of liver involvement with a repeat scan every three months from
the initial first dose of treatment to evaluate response as well as
planned re-treatment. For diffuse disease (25–50% liver tumor
burden), a planned minimum of four doses was used again of
50–100 mg (depending on the extent of tumour burden and the
extent of hepatic parenchyma reserve) irinotecan loaded into one
– two DC/LC bead vials of the similar size as above with the plan
for at least two treatments per lobe. The dosing schedule was again
repeated every 3 to 4 weeks and extended if toxicity was seen. The
patients with greater tumour burden were also followed with a
planned repeat CT scan 3 months from the first dose to evaluate
the tumour response.
Drug preparation
The saline suspension in the DC/LC bead microspheres (DEB;
Biocompatibles UK, Surrey, UK) was removed and the beads were
mixed with irinotecan solution at a dose of 50 mg per 2 ml at least
4 h before the procedure depending on the dose that was planned
to be delivered. Themixture was stored for no longer than 14 days,
and it was mixed with 5 ml of non-ionic contrast just prior to
injection.
Resection or ablation
The decision to perform resection or radio frequency ablation
(RFA) was determined at the discretion of the treating surgeon. In
the patients undergoing hepatic resections, anatomic segmental
liver resections were performed and classified as described by
Couinaud.16 Non-anatomical resections were performed when
judged appropriate by the attending surgeon. For patients with
disease that was felt to be unresectable because of the number,
distribution, and/or location of the tumours, or because of patient
co-morbid factors, ablation was performed. RFA was performed
using intra-operative ultrasound guidance to ensure that at least a
1-cm ablation margin was achieved around the tumours.17,18
Post-operative complications and the length of hospital stay
were prospectively evaluated. Complications were graded accord-
ing to a standard five-point grading scale that has been utilized
prospectively since June 2002.19,20 All in-hospital and 90-day post-
operative complications were evaluated with the highest severity
level recorded. Peri-operative complications were defined as com-
plications occurring within 30 days of the operation. RFA patients
had one early CT (<1month fromRFA) to ensure RFA success and
were then imaged per standard whereas resection patients were
imaged per standard. Standard CT follow-up was utilized every 3
months for the first year and then every 6 months thereafter. Data
were censored at the last recorded patient contact if an endpoint
was not reached. Recurrence was also evaluated using serological
markers and a PET scan. A recurrence was the re-occurrence of a
viable tumour using radiological CT criteria of a vascular mass. In
the event of subsequent hepatic therapy for recurrence of disease
only the first procedure to evaluate response was used for the
purposes of this study.
Chi-square, Student’s t-test and Mann-Whitney’s U-test for
nominal, continuous and ordinal variables were used to evaluate
the association of independent variables to surgical complica-
tions. Proportional hazards analysis was performed on all vari-
ables found significant by univariate analysis. Relative risk (RR)
with 95% confidence intervals was calculated as a measure of
association. Differences of P < 0.05 were considered significant.
Statistical analysis was performed using JMP software (JMP; SAS
Institute Inc., Cary, NC, USA).
Results
Patient and tumour characteristics
A total of 55 patients underwent 90 treatment sessions with the
irinotecan drug-eluting beads. There were 25 (45%) women and
30 (55%) men in this study with a median age of 52 years (range
42–75). Past medical histories were significant for prior cardiac
disease in seven patients, prior pulmonary disease in three
patients, underlying diabetes in eight patients, prior alcohol abuse
in five patients and tobacco abuse (median 60 pack years, range
30–120) in six patients. All of the study patients’ past medical
histories were negative for primary breast, carcinoid, renal,
ovarian, melanoma, sarcoma and lung cancers. All patients had
had their colon primary resected and 15 patients had undergone
either prior anatomic hepatic lobectomy or RFA.
The extent of liver involvement was <25% in 75% of the
patients (n = 41), between 26 and 50% in 15% of the patients (n =
11) and >50% in 10% of the patients (n = 24). The median
number of hepatic lesions was four (range 1–20), with a median
total size of all target lesions of 9 cm (range 5.5–28 cm) with 50%
of patients having bilobar tumour distribution. The median
number of irinotecan treatments was two (range 1–5). Median
treatment dose was 100 mg (range 100 mg–200 mg), and the
median total hepatic treatment dose was 200 mg (range 200–650),
with 86% of treatments being performed in a lobar infusion treat-
ment. Thirty per cent of patients were undergoing simultaneous
systemic chemotherapy. Overall response rates on evaluable
patients was acceptable, with data demonstrating that if response
could be achieved after 6 months then this portended to a more
durable response long term (Table 1).
Neo-adjuvant or downstage treatment
Eleven (20%) patients demonstrated either a significant response
and downstaging of their disease or stable disease without
Table 1 Overall response rates on patients who were treated with
irinotecan beads
3
months
6
months
12
months
18
months
Complete response 6% 7% 6% 8%
Partial response 33% 35% 50% 83%
Stable disease 52% 54% 32% 0%
Progressive disease 9% 4% 12% 8%
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extra-hepatic disease progression allowing resection, ablation or
resection and ablation (Table 2).
Ten of the 11 patients were male; all were Caucasian, with a
median age of 52 years, range 50–71. Four had non-insulin-
dependent diabetes with only two having prior tobacco history,
pack year ranging from 27 and 50 pack years, respectively. Three
had had prior right hepatic lobectomy, and three had had prior
open or percutaneous radiofrequency ablation at their initial
metastatic presentation. At the time of referral for hepatic arterial
therapy, median CEA level was 81.5 with a range of 2.6–488. All
patients had multiple liver metastases, median of five and ranging
from two to 15, with a median number of target lesions being
three, range two to five. The most common location for metastasis
was the right hepatic lobe. The single largest target lesion was a
median of 2.6 with a range of 1.5–4.6 with the cumulative target
lesions being a median of 3.5, a range of 2.6–10.1. Nine patients
had less than 25% of the liver involved with the remaining two
having 26–50% of the liver involvement. Five patients had extra-
hepatic disease involving either the lung (n = 3) or periportal
lymph node (n = 2). All patients had received prior systemic
chemotherapy, including Folfox for a median duration of eight
cycles, range 4–12 in nine patients, Folfiri in three patients with a
median of six cycles, bevacuximab in 10 patients with a median
duration of 12 cycles and five patients receiving capecitabine-
based therapy for a median duration of 5 months. Three patients
were treated with concurrent irinotecan and cetuximab-based
therapy while undergoing their hepatic arterial irinotecan bead
treatments. The remaining patients received irinotecan bead
therapy alone.
The median number of irinotecan bead treatments in the
operative group was three with a range of 1–3 treatments. Prior
to treatment, all patients had a normal haemotological and
hepatic synthetic function. All patients were treated with a single
vial of beads loaded with 100 mg of irinotecan in a lobar infu-
sion, either to the right or left hepatic artery. A variety of bead
sizes were utilized with six treatments performed with 100- to
300-micron beads, seven treatments occurring with 300- to 500-
micron beads and five treatments occurring with 500- to 700-
micron beads. The total planned dose was given in all treatments
except three in which 60%, 90% and 90% of the dose was
administered prior to the development of complete stasis. After
hepatic arterial bead treatment, the median length of stay was
23 h with a range of 23 h to 2 days. One patient suffered an
adverse event consisting of post-embolic syndrome on day five,
defined as nausea and emesis requiring outpatient intravenous
hydration. Median observation time between last bead treatment
and operation was 6 months with a range of 3 to 9 months to
better confirm response to treatment, biology of the underlying
disease and confirm stabilization or eradication of possible
extrahepatic disease.
Six out of the 11 operative patients underwent hepatic resection
which included three hepatic lobectomies and three atypical
resections. Three patients underwent radiofrequency ablation
alone and two patients underwent a combination of ablation and
resection. There were no peri-operative mortalities, with two
patients (18%) suffering complications during their peri-
operative recovery. One included a post-operative biloma that
required percutaneous drainage; the other was a minor wound
infection that required oral antibiotics. The median length of stay
of all 11 patients was 2 days with a range of 1–7 days.
Pathological assessment of the resected specimens showed
minimal nonspecific portal chronic inflammation without evi-
dence of fibrosis, or chemotherapy associated steatohepatitis
(Fig. 1). The pathologic response also demonstrated of microbead
clumping around the tumor capsule with minimal distribution
in the non-tumourous liver. (Fig. 1) The overall pathological
response rate in the resected specimens was 90%, range 30–90%
degree of necrosis.
Table 2 Clinical demographics of patients down staged or bridged to resection with irinotecan beads
Patient Prior liver
therapy
Cause for unresectablity
and reason for initial
bead treatment
No. of bead
treatments
Operation after
bead therapy
1 Lobectomy Insufficient Remnant liver 2 Ablation
2 Lobectomy Number and location 2 Ablation
3 Lobectomy Location 1 Ablation
4 Ablation Location 2 Ablation + Resection
5 Ablation Number and location 2 Ablation + Resection
6 Ablation Number and location 2 Atypical Resection
7 None Lung mets 3 Lobectomy
8 None Lung mets 3 Atypical Resection
9 None Lung mets 3 Atypical Resection
10 None Portal LN 3 Lobectomy
11 None Portal LN 3 Lobectomy
LN, lymph nodes
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After a median follow-up of 12 months after resection/ablation
on all 11 patients treated, 9 patients had recurrence with a median
disease free-interval of 9 months (range 6–18), with the most
common (80%) being extrahepatic recurrence. Median overall
survival after the operation was 12 months, with all patients cur-
rently alive.
Discussion
The multidisciplinary management of metastatic colorectal is
becoming far more complex and far more collaborative in the
optimal treatment of patients with metastatic colorectal cancer.
Given the ever increasing incidence of disease, this type of multi-
disciplinary management and collaboration is integral to the
success and quality of life of the patient.
Currently, the standard treatment for primarily resectable liver
metastases from colorectal cancer is a curative metastatic resec-
tion. However, despite curative resection 67–85% of patients
experience hepatic recurrence within 5 years and 65–72% of the
patients die making multimodal therapies worth investigating.
The neoadjuvant treatment of resectable colorectal cancer
metastases is a relatively new concept with few studies reported to
date. As such the long-term benefits are still under investigation.
There are a number of potential benefits of neoadjuvant therapy
of resectable CRC metastases such as:
• testing the chemoresponsiveness of patients in order to deter-
mine suitable adjuvant treatment post resection;
• neoadjuvant therapymay eliminate micrometastatic disease and
dormant cancer cells in the liver and may decrease the risk of
intra-operative dissemination of cells; and
• it may improve the rate of complete resection and decrease the
amount of liver that needs to be removed at surgery.
In addition, some recent studies have suggested that response to
neoadjuvant therapy may be an important prognostic factor
enabling selection of good candidates for resection. There are,
however, a number of potential drawbacks such as hepatic damage
which may affect post-operative outcome, and delay of resection
leading to disease progression.
The utilization of precision hepatic arterial irinotecan infusion
as a monotherapy or in conjunction with current systemic
chemotherapy opens up multiple opportunities in optimizing
patients with high-risk metastatic colorectal cancer. Given the fact
that response rates in second- and third-line systemic chemo-
therapeutic treatments are as low as 5–10% with significant added
toxicity a more precise chemotherapeutic delivery to reduce these
side-effects and to maximize response rates is a potential optimal
treatment algorithm. A more precise delivery option is appealing
as even patients who are responding to chemotherapy often have
to stop because of ongoing neurological, hematological and gas-
trointestinal side effects.
In the management of metastatic colorectal cancer, hepatic-
directed therapy is a well-established therapy ranging from
hepatic arterial infusion pumps21 to conventional TACE22 to
implantable infusaports.23 The rationale and clinical success of
hepatic arterial therapy is well established but can be plagued by
significant adverse events including both the need for surgical
intervention,24 biliary sclerosis,17 significant systemic exposure23
and catheter dislodgement and misplacement leading to inadvert-
ent aqueous extrahepatic infusion. LC/DC bead loaded with
irinotecan has potential advantages that overcome all of the
limitations of prior hepatic arterial-directed therapies. It is a
more precision-directed device with minimal-to-no systemic side
effects as has been reported in prior in vitro and in vivo studies.13,25
The data presented here demonstrated no evidence of irinotecan
systemic adverse events and all of our adverse events were related
to the hepatic-directed therapy. All adverse events related to bead
treatments, on review, appear to be technically related that can be
improved with adjustments in bead technique.
The ability to administer effective high-dose cytotoxic irinote-
can without inducing significant hepatic insufficiency, specifically
steatohepatitis, is of utmost importance to hepatobiliary surgeons.
Our data demonstrated no evidence of significant steatohepatitis
even with the use of precision-based irinotecan predominantly
related to point-directed chemotherapeutic effects that occur with
the precision-based beads. The fact that metastatic colorectal
cancer derives 95–100% of its blood supply from the arterial
Figure 1 Pathological evaluation of a resected liver specimen with (A) embolic beads in tumour and (B) embolic beads at the interface
between the tumour and the normal liver
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system in comparison to the normal liver which derives 90% of its
blood supply from the portal venous system allows for the point-
directed chemotherapy to be administered without clinically
significant non-tumorous hepatic toxicity, thus, making surgical
resection and even aggressive surgical resection safe without the
significant short-term and long-term toxicity that has been
reported with intravenous irinotecan in the past.
This initial pilot evaluation confirms the activity of this device in
the management of colorectal cancer liver metastasis. The present
study also demonstrates that precision hepatic arterial irinotecan
therapy is a safe and effective treatment option in themanagement
of patients with metastatic colorectal. Hepatic arterial infusion
irinotecan drug-eluting beads is an acceptable therapy for evaluat-
ing the overall metastatic biology of the metastatic colorectal
cancer to the liver prior to planned hepatic resection.
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